Status:
RECRUITING
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Lead Sponsor:
Arrowhead Pharmaceuticals
Conditions:
Alzheimer Disease
Alzheimer Disease, Early Onset
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's diseas...
Eligibility Criteria
Inclusion
- Inclusion Criteria (All Participants):
- Body mass index between 18.0 and 35.0 kg/m\^2 at Screening
- Not pregnant or breast-feeding
- Able and willing to provide written informed consent prior to the performance of any study specific procedures
- Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later; participants must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later
- Inclusion Criteria (Alzheimer's Disease):
- Adults aged 50 to 75 years of age with a clinical diagnosis of early AD and plasma, CSF, or imaging biomarkers consistent with the diagnosis
- On stable doses of AD-related medications for at least 8 weeks prior to Screening Visit and throughout the Screening period until Day 1
- Exclusion Criteria (All Participants):
- Uncontrolled hypertension
- Human immunodeficiency virus (HIV) infection (seropositive at Screening)
- Seropositive for hepatitis B (HBV) or hepatitis C (HCV) at Screening
- Intellectual disability or significant behavioral neuropsychiatric manifestation
- Clinically significant cardiac, liver, or renal disease
- Any contraindications to lumbar puncture
- Note: Additional inclusion/exclusion criteria may apply per protocol.
Exclusion
Key Trial Info
Start Date :
November 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT07221344
Start Date
November 18 2025
End Date
June 1 2027
Last Update
December 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site 1
Grafton, Auckland, New Zealand, 1010